Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal CD73 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Liposomal CD73 siRNA is an experimental RNA interference (RNAi) therapeutic consisting of small interfering RNA (siRNA) targeting the CD73 ectonucleotidase, encapsulated within a liposomal nanoparticle. CD73 is an enzyme that converts extracellular adenosine monophosphate (AMP) into adenosine, a potent immunosuppressive molecule in the tumor microenvironment. By silencing CD73 expression, this drug aims to reduce adenosine levels, thereby relieving immunosuppression and enhancing the activity of cytotoxic CD8+ T cells. In specific research formulations, the liposome is functionalized with the GE11 peptide to target the Epidermal Growth Factor Receptor (EGFR) on tumor cells, improving delivery and efficacy. It has been studied primarily in preclinical models of metastatic breast cancer, often in combination with chemotherapy like liposomal doxorubicin.
- Other names
- GE11-liposomal CD73 siRNAGE-11-liposomal CD73 siRNAGE 11-liposomal CD73 siRNAGE11-Lipo CD73 siRNAGE-11-Lipo CD73 siRNAGE 11-Lipo CD73 siRNAEGFR-targeted liposomal CD73 siRNA
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on liposomal CD73 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal CD73 siRNA.